Get the Stockscreener App
0.71
0.57%
-0.0041
Pre-market:
.71
Maxcyte Inc stock is traded at $0.71, with a volume of 620.90K.
It is down -0.57% in the last 24 hours and down -9.25% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$0.7141
Open:
$0.7011
24h Volume:
620.90K
Relative Volume:
0.56
Market Cap:
$75.87M
Revenue:
$33.03M
Net Income/Loss:
$-44.63M
P/E Ratio:
-1.6933
EPS:
-0.4193
Net Cash Flow:
$-36.18M
1W Performance:
+1.07%
1M Performance:
-9.25%
6M Performance:
-54.19%
1Y Performance:
-71.26%
1-Day Range:
$0.6748
$0.7246
1-Week Range:
$0.6748
$0.7619
52-Week Range:
$0.6434
$2.955
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.71 | 75.87M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
101.83 | 176.95B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.07 | 127.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.42 | 110.95B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
61.86 | 91.93B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.84 | 46.61B | 6.07B | 1.06B | 1.34B | 1.8063 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Quarterly Earnings: Is MaxCyte Inc stock a value trap2026 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI
MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - Stock Titan
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - Stock Titan
RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - GuruFocus
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds By Investing.com - Investing.com Australia
Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat
Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com
Stifel cuts MaxCyte stock price target on 2026 revenue guidance By Investing.com - Investing.com Australia
MaxCyte 2025 Financial Results Review - AlphaStreet
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
MaxCyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript - insidermonkey.com
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... By GuruFocus - Investing.com Canada
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts - Investing.com
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts By Investing.com - Investing.com Australia
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):